EXHIBIT 99.1
Published on August 5, 2016
NOTICE OF CHANGE IN FISCAL YEAR END
Section 4.8 of National Instrument 51-102
TO: Autorité des marchés financiers
Alberta Securities Commission
British Columbia Securities Commission
Manitoba Securities Commission
Ontario Securities Commission
This Notice is provided pursuant to the requirements of Part 4.8 of National Instrument 51‑102 – Continuous Disclosure Obligations.
|
1. Change of Financial Year End
|
Acasti Pharma Inc. (the "Corporation") has decided to change its fiscal year end from February 28 to March 31.
| 2. | Reason for the Change |
This step is being taken to allow the Corporation to be better aligned with its industry comparables and standard quarters.
| 3. | Date of Old Financial Year End |
February 28
| 4. | Date of New Financial Year End |
March 31
| 5. | The length and ending date of the periods, including the comparative periods, of each interim financial report and the annual financial statements to be filed for the Corporation's transition year and its new financial year |
|
Transition Year
|
Comparative Annual Financial Statements to Transition Year
|
New Financial Year
|
Comparative Annual Financial Statements to New Financial Year
|
Interim Periods for Transition Year
|
Comparative Interim Periods to Interim Periods in Transition Year
|
Interim Periods for New Financial Year
|
Comparative Interim Periods to Interim Periods in New Financial Year
|
|
13 months ended
March 31, 2017
|
12 months
ended
February 29, 2016
|
March 31
|
13 months ended
March 31, 2017
|
3 months
ended
May 31, 2016
|
3 months
ended
May 31, 2015
|
3 months
ended
June 30, 2017
|
3 months
ended
May 31, 2016
|
|
6 months
ended
August 31, 2016
|
6 months
ended
August 31, 2015
|
6 months
ended
September 30, 2017
|
6 months
ended
August 31, 2016
|
||||
|
9 months
ended
November 30, 2016
|
9 months
ended
November 30, 2015
|
9 months
ended
December 31, 2017
|
9 months
Ended
November 30, 2016
|
||||
|
13 months
ended
March 31, 2017
|
12 months
ended
February 29, 2016
|
Dated this 5th day of August 2016
ACASTI PHARMA INC.
/s/ Jean-Daniel Bélanger
Jean-Daniel Bélanger
Corporate Secretary